Michaeli DT, Michaeli T (December 2022). "Overall Survival, Progression-Free Survival, and Tumor Response Benefit Supporting Initial US Food and Drug Administration Approval and Indication Extension of New Cancer Drugs, 2003-2021". Journal of Clinical Oncology. 40 (35): 4095–4106. doi:10.1200/JCO.22.00535. PMID35921606. S2CID251317641.
Michaeli DT, Michaeli T (July 2023). "Cancer Drug Prices in the United States: Efficacy, Innovation, Clinical Trial Evidence, and Epidemiology". Value in Health. doi:10.1016/j.jval.2023.06.020. PMID37516196.
Michaeli DT, Michaeli T (December 2022). "Overall Survival, Progression-Free Survival, and Tumor Response Benefit Supporting Initial US Food and Drug Administration Approval and Indication Extension of New Cancer Drugs, 2003-2021". Journal of Clinical Oncology. 40 (35): 4095–4106. doi:10.1200/JCO.22.00535. PMID35921606. S2CID251317641.
Michaeli DT, Michaeli T (December 2022). "Overall Survival, Progression-Free Survival, and Tumor Response Benefit Supporting Initial US Food and Drug Administration Approval and Indication Extension of New Cancer Drugs, 2003-2021". Journal of Clinical Oncology. 40 (35): 4095–4106. doi:10.1200/JCO.22.00535. PMID35921606. S2CID251317641.
Michaeli DT, Michaeli T (July 2023). "Cancer Drug Prices in the United States: Efficacy, Innovation, Clinical Trial Evidence, and Epidemiology". Value in Health. doi:10.1016/j.jval.2023.06.020. PMID37516196.
Michaeli DT, Michaeli T (December 2022). "Overall Survival, Progression-Free Survival, and Tumor Response Benefit Supporting Initial US Food and Drug Administration Approval and Indication Extension of New Cancer Drugs, 2003-2021". Journal of Clinical Oncology. 40 (35): 4095–4106. doi:10.1200/JCO.22.00535. PMID35921606. S2CID251317641.
Michaeli DT, Michaeli T (December 2022). "Overall Survival, Progression-Free Survival, and Tumor Response Benefit Supporting Initial US Food and Drug Administration Approval and Indication Extension of New Cancer Drugs, 2003-2021". Journal of Clinical Oncology. 40 (35): 4095–4106. doi:10.1200/JCO.22.00535. PMID35921606. S2CID251317641.
Michaeli DT, Michaeli T (December 2022). "Overall Survival, Progression-Free Survival, and Tumor Response Benefit Supporting Initial US Food and Drug Administration Approval and Indication Extension of New Cancer Drugs, 2003-2021". Journal of Clinical Oncology. 40 (35): 4095–4106. doi:10.1200/JCO.22.00535. PMID35921606. S2CID251317641.
thefreedictionary.com
medical-dictionary.thefreedictionary.com
"second-line drug". TheFreeDictionary.com. Archived from the original on 2019-04-02. Retrieved 2016-04-20.
"adjunct". The Free Dictionary. Archived from the original on 2016-04-19. Retrieved 2016-04-20.